CSL Behring, UniQure's Hemophilia B Gene Therapy Hits Primary Endpoint

CSL Behring and uniQure N.V.'s QURE etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified primary endpoint of non-inferiority in annualized bleeding rate (ABR) compared to baseline Factor IX (FIX) prophylactic treatment.

  • The study also achieved a secondary endpoint demonstrating statistical superiority in reducing ABR compared to baseline FIX prophylactic therapy.
  • CSL Behring plans to submit regulatory applications for marketing approval of etranacogene dezaparvovec in the U.S. and Europe in 1H of 2022.
  • ABR for all bleeds after stable FIX expression, assessed at 18 months, was 1.51 compared with the ABR of 4.19 for at least six months for the lead-in period.
  • ABR for investigator-adjudicated FIX-treated bleeds was 0.83 compared with lead-in ABR of 3.65.
  • Stable and durable FIX levels with mean FIX activity of 36.9% of normal in the full study population at 18-months, compared to a mean of 39% of normal at six months.
  • Etranacogene dezaparvovec was generally well-tolerated, with over 80% of adverse events considered mild. 
  • Related: One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels.
  • Price Action: QURE shares are down 3.24% at $28.40 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefshemophilia BPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!